In today’s cosmetic and personal care product market, claims such as “hypoallergenic,” “suitable for sensitive skin,” or “non-irritating” are powerful differentiators. Consumers want products that are gentle, safe, and less likely to cause adverse skin reactions. However, from a regulatory, scientific, and brand credibility perspective, such claims require solid evidence. One of the most accepted methods for providing that evidence is through the Repeat Insult Patch Test (RIPT), also known as the Human Repeat Insult Patch Test (HRIPT).
At CPT℠ Labs, we believe understanding what RIPT involves, its methodology, its limitations, and how it fits into your broader safety and regulatory strategy is essential for any brand making hypoallergenic claims. Here’s a breakdown of the essentials.
What Is RIPT / HRIPT?
RIPT is a clinical, in vivo test designed to assess both irritation (i.e., the degree of harshness or irritation caused by repeated exposure) and sensitization (whether repeated exposure can trigger an allergic response).
“Human Repeat Insult Patch Test” is another term used. RIPT/HRIPT are commonly used to support claims like “hypoallergenic,” “dermatologist tested,” “suitable for sensitive skin,” and “non-irritating.”
Key Components of an RIPT Study
To credibly substantiate hypoallergenic claims, a RIPT should follow a carefully designed protocol. It begins with a preliminary review of risk and ingredients. Before any human testing, the formula is analyzed for known allergens, ingredient purity, potential impurities, stability, and concentration levels. This reduces risk to participants and ensures the study is designed with safety in mind.
Next is volunteer panel selection. The reliability of RIPT data depends heavily on the diversity and size of the test group. Panels typically include 50 to 200 participants, with inclusion and exclusion criteria set to protect participants’ health while ensuring a range of demographics and skin types are represented. Some studies even incorporate subjects who are prone to skin sensitivity, giving brands stronger insight into real-world reactions.
The study itself is structured into phases of induction, rest, and challenge. During the induction phase, patches containing the test material are applied repeatedly over several weeks to assess the potential for irritation. This is followed by a rest period, during which no product is used. Finally, the challenge phase exposes subjects again to determine whether sensitization has occurred after the break.
The exposure regimen also plays a vital role in study design. Patches may be occlusive or semi-occlusive and are applied multiple times per week for several weeks. The frequency and duration of application are chosen to simulate repeated consumer use while still protecting participant safety.
Throughout the process, observation and documentation are critical. Trained dermatologists or clinicians carefully monitor participants for redness, swelling, itching, or delayed reactions. Every reaction is thoroughly documented, including onset, severity, and duration, to ensure the results are scientifically robust.
Finally, strict ethics and informed consent protocols are followed. Volunteers must be fully informed about the study, including its potential risks and their right to withdraw. All procedures adhere to international ethical guidelines and Good Clinical Practice standards, reinforcing both the safety of participants and the validity of the data.
How Long Does It Take?
Typical RIPT studies last around 6 weeks, consisting of an induction period (several weeks of repeated exposure), a rest period, and then a challenge.
Shorter patch tests (24- or 48-hour single application) or cumulative irritation studies can be done as supplementary or preliminary tests, but do not fully substitute for RIPT when making broad hypoallergenic / sensitization claims.
Interpreting Results & What “Passing” Means
No or acceptable irritation/sensitization
If no significant allergic responses are observed during the challenge, the product may be considered to have a low risk for sensitization under the tested conditions.
Thresholds of reaction
The test design often defines what constitutes a “significant” reaction, including grades for redness, edema, and other symptoms.
Limitations
Even a negative RIPT does not guarantee zero chance of an allergic reaction in all users. Some people are uniquely sensitive, and the contexts of use, including frequency, environmental factors, and a damaged skin barrier, matter.
Regulatory & Labeling Considerations
U.S. FDA
There is no federal standard or legal definition for “hypoallergenic.” Manufacturers do not have to submit evidence before labelling a product hypoallergenic. But using RIPT/HRIPT builds credibility, supports claims, and reduces the risk of regulatory or legal challenges.
EU and other regions
Regulations around cosmetic safety require a Product Information File (PIF), which includes safety assessments. While “hypoallergenic” is not always explicitly defined, supporting data (such as RIPT) helps substantiate claims under truth-in-advertising rules.
Marketing Claims
If you make a claim like “clinically-tested hypoallergenic,” “suitable for sensitive skin,” be clear about what data supports it: the number of subjects, study design, adverse events, and who evaluated it. Transparency boosts consumer trust.
Best Practices & Common Pitfalls
Best Practices
- Involve dermatologists or clinical experts in protocol design and evaluation.
- Use a panel that reflects your target consumer base, including age, ethnicity, and skin types.
- Include control products if possible, or internal baselines.
- Document everything: raw data, photos, evaluator comments.
- Maintain ethical oversight and ensure volunteers’ safety
Common Pitfalls
- Using too few subjects, or subjects who are not likely to reveal sensitization (e.g., only people without any skin sensitivity).
- Skipping challenge/rest phases.
- Using overly mild exposure (low frequency / short duration) that does not reflect real-world use.
- Over-claiming: e.g., saying “allergy proof,” which is misleading.
- Not considering ingredient impurities, unstable ingredients, or allergens formed during storage and degradation.
How We Can Help
At CPT℠ Labs, we offer full support for brands seeking to substantiate hypoallergenic claims via RIPT/HRIPT, including:
- Protocol design tailored to your formula, target use, and region.
- Volunteer panel recruitment and demographics.
- Application, monitoring, and evaluation under trained dermatological supervision.
- Complete documentation and reporting that is ready for regulatory, legal, and marketing uses.
- Supplementary tests (24-/48-hour patch, cumulative irritation, etc.) as needed.
Conclusion
Hypoallergenic claims can offer significant value for both brands and consumers, but only when supported by rigorous scientific evidence. The Repeat Insult Patch Test (RIPT/HRIPT) remains one of the gold standards for assessing irritation and risk of sensitization. Done correctly, it enables brands to make credible, defensible claims, manage risk, build trust, and differentiate in a crowded market.
If you’re developing a new product and considering hypoallergenic claims, the time to plan your RIPT strategy is now. We’re here to guide you through the entire process. Reach out today to get started.